<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>11</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>11</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Correlation Between Auto-antibodies to Survivin and MUC1 Variable Number Tandem Repeats in Colorectal Cancer</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>5557</FirstPage>
			<LastPage>5562</LastPage>
			<ELocationID EIdType="pii">27078</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Aim: The aim of this study was to investigate the frequency and correlation between auto-antibodies tosurvivin and MUC1 variable number tandem repeats (VNTR) in colorectal cancer (CRC), which can providevaluable information for the design of immunotherapeutic vaccines for this disease. &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: Enzyme-linkedimmunosorbent assays (ELISA) were used to examine the level of auto-antibodies against survivin and MUC1VNTR in the serum of 135 CRC patients and 95 healthy volunteers. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: Using mean absorbance + 2 standarddeviations (SD) of the healthy samples as a cut-off value, the positive rates of survivin and MUC1 VNTR autoantibodiesin CRC were 31.1% and 18.5%, respectively. Altogether, the survivin and MUC1 VNTR positivesamples accounted for 36.3% of the CRC patients, and 7.4% were positive for both. &lt;br/&gt;&lt;b&gt;Conclusion&lt;/b&gt;: A significantpositive correlation was found between levels of specific antibodies against survivin and MUC1 VNTR in theserum of CRC patients (r = 0.3652, P &lt; 0.0001), suggesting that vaccines against both targets would elicit immuneresponses more effectively.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Survivin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">MUC1 VNTR</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">ELISA</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">colorectal cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">auto-antibody</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27078_a4fccfcca9a7407958f767d2cf3198c1.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
